Neuphoria Therapeutics Adopts Limited-Duration Stockholder Rights Plan to Protect Integrity of Process

Core Viewpoint - Neuphoria Therapeutics Inc. has adopted a limited-duration stockholder rights plan to protect the interests of the company and its shareholders in response to significant stock accumulation by certain investors [1][2]. Summary by Sections Rights Plan Adoption - The Board of Directors has implemented a Rights Plan to ensure fair participation in any strategic review process and to provide time for informed decision-making [2][3]. - The Rights Plan aims to prevent any entity from gaining control through open-market accumulation without offering a control premium to all shareholders [2]. Rights Plan Details - A dividend of one preferred share purchase right will be issued for each outstanding share of common stock as of October 27, 2025 [4]. - The rights become exercisable if an entity acquires 15% or more of the outstanding common stock without Board approval [4]. - Holders of the rights can purchase additional shares at a market value of twice the exercise price, while those triggering the Rights Plan will have their rights voided [5]. Expiration and Additional Information - The rights will expire on October 27, 2026, unless redeemed or exchanged earlier by Neuphoria [6]. - Further details regarding the Rights Plan will be provided in a Form 8-K filing with the U.S. Securities and Exchange Commission [6]. Company Overview - Neuphoria is a clinical-stage biotechnology company focused on developing therapies for neuropsychiatric disorders [7]. - The company previously advanced its lead drug candidate, BNC-210, for social anxiety disorder and post-traumatic stress disorder but halted development following a failed Phase 3 clinical trial [7]. - Neuphoria has a strategic partnership with Merck & Co., Inc. for two drugs in early-stage clinical trials targeting cognitive deficits in Alzheimer's disease and other CNS conditions [7].